RU97114608A - METHOD FOR TREATING CEREBRAL ISCHEMIA AND CEREBRAL DAMAGE TO NEUROPROTECTIVE MEANS - Google Patents

METHOD FOR TREATING CEREBRAL ISCHEMIA AND CEREBRAL DAMAGE TO NEUROPROTECTIVE MEANS

Info

Publication number
RU97114608A
RU97114608A RU97114608/14A RU97114608A RU97114608A RU 97114608 A RU97114608 A RU 97114608A RU 97114608/14 A RU97114608/14 A RU 97114608/14A RU 97114608 A RU97114608 A RU 97114608A RU 97114608 A RU97114608 A RU 97114608A
Authority
RU
Russia
Prior art keywords
neuroprotective agent
metabolites
variants
salts
functional derivatives
Prior art date
Application number
RU97114608/14A
Other languages
Russian (ru)
Other versions
RU2194527C2 (en
Inventor
Эскил Элмер
Хироюки Учино
Маркус Киип
Мераб Кокая
Заал Кокая
Хакан Виднер
Ки Цхао
Кейко Учино
Original Assignee
Маас БиолАБ, ЛЛЦ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9500209A external-priority patent/SE520730C2/en
Application filed by Маас БиолАБ, ЛЛЦ filed Critical Маас БиолАБ, ЛЛЦ
Publication of RU97114608A publication Critical patent/RU97114608A/en
Application granted granted Critical
Publication of RU2194527C2 publication Critical patent/RU2194527C2/en

Links

Claims (9)

1. Способ лечения повреждения центральной нервной системы человека, заключающийся в введении в организм циклоспоринов, отличающийся тем, что осуществляют преобразование циклоспоринов в нейропротекторное средство путем обеспечения непосредственного его воздействия на поврежденную нервную ткань вследствие проникновения через гематоэнцефалической барьер, который предварительно открывают или создают возможность для проникновения через него нейропротекторного средства, скомпонованного в зависимости от метода введения в организм в виде лечебной эффективной дозы циклоспоринов и средства, открывающего гематоэнцефалический барьер, при соблюдении их пропорций, характера сочетания, последовательности и времени комплексного воздействия при введении.1. A method of treating damage to the central nervous system of a person, which consists in introducing cyclosporins into the body, characterized in that cyclosporins are converted into a neuroprotective agent by providing its direct effect on damaged nervous tissue due to penetration through the blood-brain barrier, which is previously opened or makes it possible to penetrate through it, a neuroprotective agent, arranged depending on the method of introduction into the body in de therapeutic effective dose of cyclosporin and means for opening the blood brain barrier, while respecting their proportions, the nature of the coupling, and the time sequence of complex effects when administered. 2. Способ по п. 1, отличающийся тем, что в качестве нейропротекторного средства используют циклоспорин А. 2. The method according to p. 1, characterized in that cyclosporin A. is used as a neuroprotective agent. 3. Способ по п. 1, отличающийся тем, что в качестве нейропротекторного средства используют функциональные дериваты, метаболиты, их варианты или соли. 3. The method according to p. 1, characterized in that as a neuroprotective agent using functional derivatives, metabolites, their variants or salts. 4. Способ по пп. 1 - 3, отличающийся тем, что нейропротекторное средство, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, варианты или их соли, вводят в организм через рот. 4. The method according to PP. 1 to 3, characterized in that the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, variants or their salts, is introduced into the body through the mouth. 5. Способ по пп. 1-3, отличающийся тем, что нейропротекторное средство, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, их варианты или соли, вводят в организм интраартериально или интравенозно. 5. The method according to PP. 1-3, characterized in that the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, their variants or salts, is introduced into the body intraarterially or intravenously. 6. Способ по пп. 1-3, отличающийся тем, что нейропротекторное средство, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, их варианты или соли, вводят парентерально. 6. The method according to PP. 1-3, characterized in that the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, their variants or salts, is administered parenterally. 7. Способ по пп. 1 и 3, отличающийся тем, что нейропротекторное средство, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, их варианты или соли, вводят в ткань мозга или прилежащие к ней области, в спиномозговую жидкость или спинной мозг. 7. The method according to PP. 1 and 3, characterized in that the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, their variants or salts, is introduced into the brain tissue or adjacent areas, into the cerebrospinal fluid or spinal cord. 8. Способ по пп. 1-7, отличающийся тем, что нейропротекторное средство, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, их варианты или соли, вводят в комбинации использования по пп. 1-7. 8. The method according to PP. 1-7, characterized in that the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, their variants or salts, is administered in a combination of use according to claims. 1-7. 9. Способ по пп. 1-8, отличающийся тем, что средство, открывающее гематоэнцефалический барьер нейропротекторного средства, содержащее циклоспорины, в том числе функциональные дериваты, метаболиты, их варианты или соли, комбинации перечисленных препаратов в чистом виде, в растворах с растворителями или добавками, содержит несколько составляющих, которые открывают гематоэнцефалический барьер через один или несколько механизмов, включающих в себя гиперосмотический раствор манитола, электростатический блокиратор протамина сульфата и ингибитора Р-гликопротеин, в комбинации использования по пп. 1-8. 9. The method according to PP. 1-8, characterized in that the tool that opens the blood-brain barrier of the neuroprotective agent containing cyclosporins, including functional derivatives, metabolites, their variants or salts, combinations of these drugs in pure form, in solutions with solvents or additives, contains several components, that open the blood-brain barrier through one or more mechanisms, including a hyperosmotic solution of mannitol, an electrostatic blocker of protamine sulfate and an inhibitor of P-glycop otein in combination use of claim. 1-8.
RU97114608/14A 1995-01-20 1996-01-18 Method for treating ischemia and cerebral lesion with a neuroprotector preparation RU2194527C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9500209A SE520730C2 (en) 1995-01-20 1995-01-20 Treatment of brain ischemia and brain damage with a neuroprotective drug
SE9500209-3 1995-01-20

Publications (2)

Publication Number Publication Date
RU97114608A true RU97114608A (en) 1999-06-20
RU2194527C2 RU2194527C2 (en) 2002-12-20

Family

ID=20396911

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97114608/14A RU2194527C2 (en) 1995-01-20 1996-01-18 Method for treating ischemia and cerebral lesion with a neuroprotector preparation

Country Status (18)

Country Link
US (1) US5972924A (en)
EP (1) EP0813420B1 (en)
JP (1) JP3643380B2 (en)
CN (1) CN1123359C (en)
AP (1) AP734A (en)
AT (1) ATE218360T1 (en)
AU (1) AU712974B2 (en)
CA (1) CA2210241C (en)
CZ (1) CZ291233B6 (en)
DE (1) DE69621603T2 (en)
DK (1) DK0813420T3 (en)
ES (1) ES2176432T3 (en)
MX (1) MX9706362A (en)
NZ (1) NZ300699A (en)
PT (1) PT813420E (en)
RU (1) RU2194527C2 (en)
SE (1) SE520730C2 (en)
WO (1) WO1996022104A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711795C2 (en) * 1997-03-21 2001-03-08 Apogepha Arzneimittel Gmbh Use of cyclosporin for the treatment of myocardial infarctions and their consequences
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
AP1040A (en) * 1998-09-17 2002-01-30 Panacea Biotec Ltd A novel composition containing cyclosporin.
CN1322136A (en) * 1998-09-23 2001-11-14 马库斯·基普 Neuroimmunophilins for selective neuronal radioprotection
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
AU766910B2 (en) * 1999-04-13 2003-10-23 North Shore-Long Island Jewish Research Institute Prevention of brain damage in stroke
EP1214293A1 (en) 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
DE19961733A1 (en) * 1999-12-21 2001-06-28 Ciclomulsion Ag Oil-in-water emulsion comprising cyclosporin, is useful for treating neurological disease and as a neuroprotectant, comprises triglyceride, natural emulsifier and a hypertonicity agent
KR20010069066A (en) * 2000-01-12 2001-07-23 이종원 Culturing Method Which Allows Growth of Animal Cells Under Hypoxic Condition
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
WO2001076517A2 (en) * 2000-04-07 2001-10-18 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and apparatus for thermally affecting tissue
WO2002028331A1 (en) 2000-10-05 2002-04-11 Seacoast Technologies, Inc. Expandable device for thermal therapy including spiral element
JP2004532187A (en) 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド Trisubstituted carbocyclic cyclophilin binding compounds and their uses
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
PL210795B1 (en) 2001-10-19 2012-03-30 Isotechnika Inc The method of producing the ISATX247 enriched isomer (E), the method of producing the ISATX247 enriched mixture of the (Z) isomer, the method of stereoselective synthesis of the (E) ISATX247 isomer, the method of stereoselective synthesis of the (Z) isomer ISATX247 and the method of producing the mixture of ISATX247 isomers
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
KR20080033331A (en) * 2005-07-05 2008-04-16 바이오템프트, 비.브이. Treatment of tumors
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
MX2009001966A (en) * 2006-08-23 2009-06-19 Univ Montana Method of reducing neuronal cell damage.
CA2677948C (en) * 2007-02-12 2014-12-09 Biotempt B.V. Treatment of trauma-hemorrhage with short oligopeptides
JP2013522311A (en) * 2010-03-15 2013-06-13 ステルス ペプチドズ インターナショナル インコーポレイテッド Combination therapy with cyclosporine and aromatic-cationic peptide
RU2475233C2 (en) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Pharmacological composition for intranasal introduction for cerebral delivery of pharmacologically active component, and method for preparing it
TR201900128T4 (en) 2010-12-15 2019-02-21 Contravir Pharmaceuticals Inc Cyclosporine analog molecules modified at amino acid 1 and 3.
CN102784102A (en) * 2012-08-28 2012-11-21 赵继红 Tetraodotoxin oral liquid state preparation and preparation method thereof
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
EP3801217A4 (en) * 2018-05-30 2022-07-20 Zap Surgical Systems, Inc. Radiosurgical neuromodlation close to critical structures
US20220296540A1 (en) 2019-09-15 2022-09-22 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds

Similar Documents

Publication Publication Date Title
RU97114608A (en) METHOD FOR TREATING CEREBRAL ISCHEMIA AND CEREBRAL DAMAGE TO NEUROPROTECTIVE MEANS
Watts et al. Effects of scopolamine on radial maze performance in rats
Jost et al. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm
Singh et al. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex.
Serota et al. Acetoxycycloheximide-induced transient amnesia: Protective effects of adrenergic stimulants
ES2147722T3 (en) METHOD TO INCREASE THE PERMEABILITY OF THE HEMATOENCEPHALIC BARRIER.
RU96115200A (en) 2,4-DISULFOFENYLBUTILNITRON, ITS SALT AND THEIR APPLICATION AS PHARMACEUTICAL SPIN TRAPS
RU97121002A (en) USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDANE, ITS SALTS AND COMPOSITIONS CONTAINING THEM
RU2007125589A (en) METHOD FOR IMPROVING THE STRUCTURE AND / OR FUNCTIONS OF ARTERIOL, ACTIVE AGENT FOR IMPROVING THE STRUCTURE AND / OR FUNCTIONS OF ARTERIOL AND KIT FOR TREATMENT OF CONDITIONS, CHARACTERIZING NENORMURALURIC ARENOLURICULT
PT1248643E (en) USEFULNESS OF COPOLYMER 1 AND CONGENERAL AND T-CELLED PEOPLE AND POLYMPEPTIDES TREATED WITH THESE COMPOUNDS FOR NEUROPROTECTING THERAPY
KR20140042926A (en) Pharmaceutical composition with synergistic anticonvulsant effect
BR9407748A (en) Pharmaceutical formulation: process for preparing the same and process for the prevention and / or treatment of neurodegeneration or for obtaining an anti-convulsive effect or sedation in a patient
ES2179843T3 (en) METHOD FOR THE SELECTIVE OPENING OF CAPABLES OF ABNORMAL BRAIN FABRIC.
BR9714677A (en) "3-pyridyl enantiomers and their use as analgesics"
ZA958173B (en) Use of a serotonin agoinist in combination with a tachykinin receptor antaonist in the treatment or prevention of migraine
Rudd et al. Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew)
PT813416E (en) REDUCING VOLUME OF FUNGUS USING CITICOLIN
ES2185153T3 (en) USE OF MEFLOQUINA (+) FOR THE TREATMENT OF MALARIA.
AR002975A1 (en) Use of at least one cgrp antagonist for the preparation of a pharmaceutical or dermatological composition to treat ocular and / or palpebral itching, pain and / or dysesthesia, as well as in a cosmetic composition for sensitive eyes, an obenide composition and a procedure using said cosmetic composition.
ZA972601B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
KR910002442A (en) Methods and pharmaceutical compositions for treating ocular disease
Buccafusco et al. Role of cholinergic neurons in the cardiovascular responses evoked by central injection of bradykinin or angiotensin II in conscious rats
Kaplan Focal seizures resembling transient ischemic attacks due to subclinical ischemia
BILOBA 17. IN VIVO STUDIES OF THE PHARMACOLOGICAL AND BIOCHEMICAL ACTIVITIES OF GINKGO BILOBA EXTRACT (EGb 761) AND ITS CONSTITUENTS